RAPID
A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 40 patients (estimated)
- Collaborators
- Moffitt Cancer Center, The University of Kansas Medical Center
- Tags
- T Cell (Allogeneic), High Risk
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 2144
- NCT Identifier
- NCT06552416
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.